Molecular Pathology of Non-Small Cell Lung Cancer A Practical Guide
Molecular Pathology of Non-Small Cell Lung Cancer A Practical Guide
复制标题
DOI：
10.1309/ajcpfr12wjkceezz
复制
发表时间：
2012-09-01
影响因子：
3.5
通讯作者：
Marshall, Carrie B.
中科院分区：
文献类型：
--
作者：
Aisner, Dara L.;Marshall, Carrie B.
小细胞肺癌和非小细胞肺癌(NSCLC)之间的传统区别不再足以用于治疗计划。建议谨慎处理小的诊断样本，因为它们通常是唯一可用于分子分析的样本。病理学家面临着根据极小的肿瘤样本对肺癌进行细分的压力，因为NSCLC肿瘤亚型现在是决定分子检测策略的关键。评估EGFR突变和ALK重排现在被认为是晚期肺腺癌治疗的标准。免疫组织化学染色有助于NSCLC的细分，但进行这些辅助研究可以显著减少可用于分子检测的组织数量，需要仔细平衡这两种需求。病理学家在促进临床肿瘤护理团队和分子实验室之间清晰和及时的沟通方面发挥着关键作用，以确保订购适当的测试并提交最佳材料进行测试。
The traditional distinction between small cell lung cancer and non small cell lung cancer (NSCLC) is no longer sufficient for treatment planning. It is advised to handle small diagnostic specimens prudently because they are often the only specimen available for molecular analysis. Pathologists are experiencing pressure to subclassify lung carcinoma based on extremely small tumor samples, because NSCLC tumor subtyping is now essential to determine molecular testing strategies. Evaluation for EGFR mutations and ALK rearrangements are now considered to be the standard of care in advanced-stage pulmonary adenocarcinomas. Immunohistochemical stains can aid in subclassifying NSCLC, but performing these ancillary studies can significantly reduce the quantity of tissue available for molecular tests, requiring careful balancing of these 2 needs. The pathologist plays a pivotal role in facilitating clear and timely communication between the clinical oncology care team and the molecular laboratory to ensure that the appropriate tests are ordered and optimal material is submitted for testing.